Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Quantitative Expression and Inter-Individual Variability of Skin Proteins Involved in Drug and Excipient Metabolism and Transporters Using Targeted and Label Free LC MS/MS Proteomics

Award Number: U01FD007348
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2021
PERIOD OF PERFORMANCE END DATE: 09/19/2025

Group Awards By:

View Award Description

Quantitative Expression and Inter-Individual Variability of Skin Proteins Involved in Drug and Excipient Metabolism and Transporters Using Targeted and Label Free LC MS/MS Proteomics - Project summary There are only few genetic alternatives for complex drug products such as the dermal formulations. This is because establishing bioequivalence (BE) for dermatological drug products by conducting comparative clinical endpoint studies can be costly and the studies may not be sufficiently sensitive to detect certain formulation differences (Tsakalozou et al 2021). Establishing in silico models such as physiologically-based pharmacokinetic (PBPK) might help with creation of alternative BE path without heavy reliance on large human clinical studies. However, robustness of such PBPK models and their advantages for answering the regulatory questions relay of sufficiency of system (non-drug-related) information supplied to them. The interaction of drug and formulation ingredients with the constituents of the skin (such as enzymes and proteins) determines the fate of the drug and exertion of its therapeutic effects. These might be highly non-linear and they may vary depending on the condition of the skin (health/disease) as well as location in the body and the attributes of the population (age, ethnicity etc). In this project, the principal enzymes and transporters of the human skin, which are relevant to both active moiety of dermal products as well as the ingredients in the formulation, will be quantified using variety of high resolution tandem mass spectrometry based proteomics measurements. This will be achieved by a collaboration between academia, industry and the FDA and will address the ongoing interest in providing robust in silico models for transdermal drug delivery systems. These data are necessary for populating physiologically based pharmacokinetic (PBPK) models of drug metabolism and disposition (including but not limited to those housed by the Simcyp Simulator) of human skin. The aim is to achieve very broad coverage of relevant proteins and, to this end, a global proteomic approach will be adopted. Proteomic studies are labour intensive and the current published data on skin is limited to few samples. We increase this to over 100 and attempt to stratify based on various attributes. In particular we will address potential ethnic differences focussing initially on Caucasian population and African-Caribbean individuals. All data will be used to populate the Simcyp MechaDema PBPK model in first instance to create an immediate path for practical use by pharmaceutical scientists however the data will remain open for all modellers engaged with PBPK.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	THE UNIVERSITY OF MANCHESTER	OXFORD ROAD	MANCHESTER				GBR	Food and Drug Administration Research	001	3	9/5/2024	NON-COMPETING CONTINUATION	$0
2024	2023	THE UNIVERSITY OF MANCHESTER	OXFORD ROAD	MANCHESTER				GBR	Food and Drug Administration Research	000	3	8/19/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $248,810 )
2023	2023	THE UNIVERSITY OF MANCHESTER	OXFORD ROAD	MANCHESTER				GBR	Food and Drug Administration Research	001	3	7/31/2023	NON-COMPETING CONTINUATION	$248,810
2023	2022	THE UNIVERSITY OF MANCHESTER	OXFORD ROAD	MANCHESTER				GBR	Food and Drug Administration Research	000	2	1/10/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $248,810

Issue Date FY: 2022 ( Subtotal = $299,568 )
2022	2022	UNIVERSITY OF MANCHESTER	OXFORD RD	MANCHESTER	LANCASHIRE			GBR	Food and Drug Administration Research	000	2	7/22/2022	NON-COMPETING CONTINUATION	$299,568
														Subtotal = $299,568

Issue Date FY: 2021 ( Subtotal = $296,354 )
2021	2021	UNIVERSITY OF MANCHESTER	OXFORD RD	MANCHESTER	LANCASHIRE			GBR	Food and Drug Administration Research	001	1	9/29/2021	NEW	$0
2021	2021	UNIVERSITY OF MANCHESTER	OXFORD RD	MANCHESTER	LANCASHIRE			GBR	Food and Drug Administration Research	000	1	9/21/2021	NEW	$296,354
														Subtotal = $296,354

Grand Total All Awards = $844,732

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Quantitative Expression and Inter-Individual Variability of Skin Proteins Involved in Drug and Excipient Metabolism and Transporters Using Targeted and Label Free LC MS/MS Proteomics

Award Number: U01FD007348

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2021

PERIOD OF PERFORMANCE END DATE: 09/19/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer